-
公开(公告)号:US20220267751A1
公开(公告)日:2022-08-25
申请号:US17626168
申请日:2020-07-10
Applicant: Monash University
Inventor: James Whisstock , Ruby Law , Adam Quek , Paul Conroy
Abstract: The present invention relates to methods of producing recombinant plasminogen in a mammalian expression system. A method for producing plasminogen, the method comprising (i) providing a host cell comprising a first recombinant polynucleotide encoding plasminogen and a second recombinant polynucleotide encoding a plasminogen activation inhibitor; (ii) culturing said host cell in a suitable culture medium under conditions to effect expression of plasminogen from the first polynucleotide and plasminogen activation inhibitor from the second polynucleotide.
-
公开(公告)号:US11304954B2
公开(公告)日:2022-04-19
申请号:US16955162
申请日:2018-12-19
Applicant: PureTech LYT, Inc. , Monash University
Inventor: Daniel Kenneth Bonner , Ketki Karanam , Sifei Han , Luojuan Hu , Christopher John Hamilton Porter , Tim Quach , Rishab R. Shyam , Jamie Simpson , Natalie Trevaskis
IPC: C07D413/12 , A61K31/5377 , A61K47/54 , A61P37/06
Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
-
公开(公告)号:US20220008481A1
公开(公告)日:2022-01-13
申请号:US17328966
申请日:2021-05-24
Applicant: HUDSON INSTITUTE OF MEDICAL RESEARCH , MONASH UNIVERSITY
Inventor: Euan Wallace , Rebecca Lim
Abstract: The present disclosure relates generally to the methods of treatment of mammalian subjects by an enhanced cell-based therapeutic approach in order to facilitate tissue and neuronal repair, regeneration and/or reparation. Medicaments useful in the treatment of mammalian subjects and methods of production of the medicaments are also encompassed by the present disclosure.
-
公开(公告)号:US20210340547A1
公开(公告)日:2021-11-04
申请号:US17365260
申请日:2021-07-01
Applicant: Monash University
Inventor: Siew Yeen Chai , Robert Widdop , Tracey Gaspari , Huey Wen Lee
IPC: C12N15/113 , A61K31/351 , A61K31/4433 , A61K31/4709 , A61K31/55 , A61P1/16 , A61P9/00 , A61P13/12 , A61K31/395
Abstract: The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.
-
公开(公告)号:US20210325505A1
公开(公告)日:2021-10-21
申请号:US17253607
申请日:2019-05-30
Applicant: MONASH UNIVERSITY
Inventor: Stefanie Cincotta , Adrian Neild , Jean Armstrong
IPC: G01S5/16 , H04B10/116 , G01S1/70
Abstract: A visible light positioning receiver arrangement for obtaining spatial position information of the receiver arrangement from a plurality of luminaires (5), at least one of the luminaires including at least one associated modulated light source for transmitting a light signal providing positional information of one or more reference points associated with the luminaire, said receiver arrangement including: an imaging receiver for capturing an image of the luminaires and associated said reference point(s); and a non-imaging receiver (7) for estimating an angle of arrival (AOA) of light from each said modulated light source, and for decoding the reference point positional information therefrom; wherein said AOA information and reference point positional information from the non-imaging receiver is matched to the image captured by the imaging receiver to obtain said spatial position information.
-
公开(公告)号:US20210299447A1
公开(公告)日:2021-09-30
申请号:US17346971
申请日:2021-06-14
Applicant: MONASH UNIVERSITY
Inventor: Paul B FITZGERALD , Caley M. Sullivan , Richard H. THOMSON
Abstract: Closed-loop transcranial stimulation and monitoring is disclosed that includes generating a stimulation signal having a set of first oscillation parameters; applying the stimulation signal transcranially to a patient; monitoring the stimulation signal as applied to the patient; receiving a brain activity signal from the patient; generating a feedback signal based on the monitored stimulation signal as applied to the patient; and generating a modified activity signal by subtracting the feedback signal from the brain activity signal; determining one or more second oscillation parameters of the modified activity signal; and adjusting the set of first oscillation parameters of the stimulation signal based on the one or more second oscillation parameters of the modified activity signal. Closed-loop transcranial stimulation and monitoring is also disclosed in which the patient is engaged in a cognitive task.
-
公开(公告)号:US20210283160A1
公开(公告)日:2021-09-16
申请号:US17201621
申请日:2021-03-15
Applicant: Monash University , Melbourne Health
Inventor: Kylie Michelle WAGSTAFF , Leon CALY , David JANS
IPC: A61K31/7048 , A61K31/365
Abstract: The technology relates to the use of at least one macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.
-
公开(公告)号:US11078488B2
公开(公告)日:2021-08-03
申请号:US16984996
申请日:2020-08-04
Applicant: Monash University
Inventor: Siew Yeen Chai , Robert Widdop , Tracey Gaspari , Huey Wen Lee
IPC: A61K31/395 , A61K31/351 , A61K31/4433 , C12N15/113 , A61K31/4709 , A61K31/55 , A61P1/16 , A61P9/00 , A61P13/12
Abstract: The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.
-
公开(公告)号:US20210078076A1
公开(公告)日:2021-03-18
申请号:US16611897
申请日:2018-05-10
Applicant: Monash University
Inventor: Marten Jurg , Andrey Molotnikov
Abstract: An additive manufacturing system and method is provided for fabricating 3D objects (16) from successive layers (14) of material. The additive manufacturing system (10) has an energy projection assembly (20) for inputting energy (22) into a specified area within the layer (18) to consolidate the material; a plurality of image sensors (30, 32, 34), each of the image sensors having a corresponding field of view (35, 40, 42) covering at least part of the layer (18) of material, such that each of the fields of view at least partially overlap with the field of view of at least one other of the image sensors; and an image processor (56) to capture image data from each of the image sensors (30, 32, 34). The image processor (56) controls exposure times for each of the image sensors (30, 32, 34) and combines the image data from the image sensors to provide a single, spatially resolved image of the energy being input throughout the specified area for each layer (14) of material respectively for comparison against threshold data values to locate potential consolidation defects in the specified area.
-
公开(公告)号:US20200291502A1
公开(公告)日:2020-09-17
申请号:US16753480
申请日:2018-10-08
Applicant: MONASH UNIVERSITY
Inventor: Xinhua WU , Xigen ZHOU
Abstract: A “modified” meta-stable # titanium alloy that, apart from carbon content, corresponds to the composition range for standard Beta-C titanium alloy. The modified alloy comprises vanadium, chromium, molybdenum, zirconium, aluminium, with maxima for oxygen, iron, nitrogen, hydrogen, yttrium, and other elements (apart from carbon and titanium), with a balance (apart from carbon) of titanium. The modified alloy has carbon present at a stable total carbon level sufficiently in excess of 0.05 wt. % achieving an improvement in the mechanical properties of UTS, DSS and fatigue strength in threaded regions, relative to standard Beta-C alloy with a specified carbon level below 0.05 wt. %, with a maximum carbon content controlled so as to preclude carbide formation having a detrimental effect on the level of fatigue strength.
-
-
-
-
-
-
-
-
-